A second trial has affirmed that cancer drug Avastin ( bevacizumab ) is an effective cost efficient treatment for patients suffering from age-related macular degeneration (AMD), which can lead to blindness.

Two medications commonly used to treat age-related macular degeneration (AMD) have been found to provide equal treatment benefit in the first long-term study comparing the drugs.  Injectable drugs Avastin ( bevacizumab ), an off-label cancer medication most frequently used to treat AMD, and Lucentis ( ranibizumab ), approved to treat AMD by the U.S. Food and Drug Administration in 2006, both provided similar vision improvements at two years. Get regular vision exams to pinpoint vision loss early. Maureen Maguire, PhD, corresponding author and director of the Center for Preventi...